Impact of left atrial volume, sphericity, and fibrosis on the outcome of catheter ablation for atrial fibrillation

Introduction To investigate the relation between left atrial (LA) volume, sphericity, and fibrotic content derived from contrast‐enhanced cardiac magnetic resonance imaging (CE‐CMR) and their impact on the outcome of catheter ablation for atrial fibrillation (AF). Methods and results In 83 patients...

Full description

Saved in:
Bibliographic Details
Published inJournal of cardiovascular electrophysiology Vol. 29; no. 5; pp. 740 - 746
Main Authors den Uijl, Dennis W., Cabanelas, Nuno, Benito, Eva M., Figueras, Rosa, Alarcón, Francisco, Borràs, Roger, Prat, Susanna, Guasch, Eduard, Perea, Rosario, Sitges, Marta, Brugada, Josep, Berruezo, Antonio, Mont, Lluís
Format Journal Article
LanguageEnglish
Published United States Wiley Subscription Services, Inc 01.05.2018
Wiley
Subjects
Online AccessGet full text
ISSN1045-3873
1540-8167
1540-8167
DOI10.1111/jce.13482

Cover

More Information
Summary:Introduction To investigate the relation between left atrial (LA) volume, sphericity, and fibrotic content derived from contrast‐enhanced cardiac magnetic resonance imaging (CE‐CMR) and their impact on the outcome of catheter ablation for atrial fibrillation (AF). Methods and results In 83 patients undergoing catheter ablation for AF, CE‐CMR was used to assess LA volume, sphericity, and fibrosis. There was a significant correlation between LA volume and sphericity (R  =  0.535, P < 0.001) and between LA volume and fibrosis (R  =  0.241, P  =  0.029). Multivariate analyses demonstrated that LA volume was the strongest independent predictor of AF recurrence after catheter ablation (1.019, P  =  0.018). Conclusion LA volume, sphericity, and fibrosis were closely related; however, LA volume was the strongest predictor of AF recurrence after catheter ablation.
Bibliography:This work was supported by the European Union's Horizon 2020 research and innovation programme under grant agreement No. 633196 (CATCH ME project); Instituto de Salud Carlos III (ISCIII), PI16/00703; Instituto de Salud Carlos III (ISCIII), PI16/00435; Instituto de Salud Carlos III (ISCIII), CIBERCV16: CB16/11/00354; Fundació la Marató de TV3. 20152730. CERCA Programme / Generalitat de Catalunya.
L. Mont., J. Brugada, and A. Berruezo are shareholders of Galgo Medical Company. Other authors: No disclosures.
Funding Information
DWdU and NC have contributed equally to the paper.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1045-3873
1540-8167
1540-8167
DOI:10.1111/jce.13482